# Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

Study · id `cardio:ct-nct01790308` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01790308](<https://clinicaltrials.gov/study/NCT01790308>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01790308

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT01790308. Randomized; no masking; primary purpose treatment. Start 2013-02 (registry gives no type); primary completion 2014-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT01790308, source copy `cardio:ctgov-nct01790308-2013-02-13`, retrieved 2026-10-26)
- Start date: 2013-02 (registry gives no type) (ClinicalTrials.gov record NCT01790308, source copy `cardio:ctgov-nct01790308-2013-02-13`, retrieved 2026-10-26)
- Primary completion: 2014-12 (anticipated) (ClinicalTrials.gov record NCT01790308, source copy `cardio:ctgov-nct01790308-2013-02-13`, retrieved 2026-10-26)
- Completion: 2015-12 (anticipated) (ClinicalTrials.gov record NCT01790308, source copy `cardio:ctgov-nct01790308-2013-02-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01790308-2013-02-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): CSII
- Intervention (Drug): Liraglutide
- Lead sponsor: Sun Yat-sen University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Sun Yat-sen University (`cardio:org-sun-yat-sen-university`)

## Provenance

Content hash: 91ea1a505bf701a809e48b7110683085818bf3636bc21357aa1d27fc806f77cf
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
